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PCLINICAL RESEARCH Heart Failure
Transpulmonary B-Type Natriuretic Peptide
Uptake and Cyclic Guanosine Monophosphate
Release in Heart Failure and Pulmonary Hypertension
The Effects of Sildenafil
Vojtech Melenovsky, MD, PHD, Hikmet Al-Hiti, MD, Ludmila Kazdova, PHD,
Antonin Jabor MD, PHD, Petr Syrovatka, MD, Ivan Malek, MD, PHD, Jiri Kettner, MD, PHD,
Josef Kautzner MD, PHD
Prague, Czech Republic
Objectives We sought to identify factors that discriminate heart failure (HF) patients with normal and elevated pulmonary vascu-
lar resistance (PVR) and to elucidate the role of cyclic guanosine monophosphate (cGMP)-dependent vasodilation.
Background Mechanisms of PVR increase in patients with chronic HF are incompletely understood.
Methods Twenty-two HF patients with high pulmonary vascular resistance (H-PVR) (200 dyn·s·cm5) were compared
with 24 matched low pulmonary vascular resistance (L-PVR) patients of similar age, sex, body size, HF severity,
and volume status who were undergoing invasive hemodynamic study. Pulmonary arterial (PA) and venous
blood samples from a wedged PA catheter were used to calculate transpulmonary B-type natriuretic peptide
(BNP) uptake and cGMP release. The H-PVR patients were re-examined 1 h after a 40-mg oral dose of sildenafil.
Results Although transpulmonary BNP uptake was similar (p  0.2), cGMP release was diminished in the H-PVR pa-
tients (1.9 vs. 27.8 nmol·min1; p  0.005). Transpulmonary BNP uptake and cGMP release correlated in the
L-PVR patients (R  0.6, p  0.004) but not in the H-PVR. The H-PVR patients also had lower PA compliance,
systemic arterial compliance (by 47% and 20%, p  0.001 and p  0.03), and cardiac index. Sildenafil reduced
PVR (47%), systemic resistance (24%) and heart rate (8%), increased cardiac index (24%), and PA com-
pliance (87%, all p  0.001), with a parallel increase of cGMP release (from 5.6 to 16.5 nmol·min1, p 
0.047), without affecting BNP uptake or norepinephrinePA. The PVR response was not dependent on PA wedge
pressure or pulmonary hypertension reversibility with prostaglandin E1.
Conclusions The H-PVR patients have stiffening of both pulmonary and systemic arteries, preserved transpulmonary BNP up-
take, but diminished cGMP release, which is reversible by the administration of sildenafil. This study provides in
vivo evidence that phosphodiesterase 5A inhibition restores sensitivity of pulmonary vasculature to endogenous
cGMP-dependent vasodilators. (J Am Coll Cardiol 2009;54:595–600) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.021t
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vulmonary hypertension (PH) occurs in up to 70% of
atients with moderate-to-advanced heart failure (HF) (1),
dversely affecting right ventricular function, exercise capac-
ty, and survival (2–5). Pulmonary hypertension in HF is
ften due to transmission of elevated left ventricular (LV)
lling pressure into pulmonary circulation, but some pa-
rom the Department of Cardiology, Institute of Clinical and Experimental Medicine–
KEM, Prague, Czech Republic. Supported by grants MZO-00023001 and IGA
ZCR 9400-3/2007 from the Ministry of Health, MSMT-1M0510 from the
inistry of Education, and 305/09/1390 from the Grant Agency of the Czech
epublic. Dr. Kautzner is an advisory board member for Medtronic, Biosense
ebster, and GE Healthcare.m
Manuscript received February 9, 2009; revised manuscript received March 30,
009, accepted May 6, 2009.ients also develop an elevation of pulmonary vascular
esistance (PVR) (1). The mechanisms of PVR increase are
ncompletely understood, although structural remodeling of
ulmonary vasculature and vasomotor imbalance have been
mplicated (6). Besides endothelin, nitric oxide, and pros-
aglandins, pulmonary vascular tone is regulated by natri-
retic peptides (NPs) (7), which cause cyclic guanosine
onophosphate (cGMP)-dependent vasodilation (8). In
atients with HF, circulating NPs typically are increased,
ut their organ effects diminish with disease progression (9).
Decreased sensitivity of pulmonary vessels to endogenous
asodilators, reflected by low rate of local cGMP release,
ay explain the propensity of patients with HF to develop
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Pulmonary Hypertension in HF August 11, 2009:595–600PH. Whether pulmonary cGMP
release differs between HF pa-
tients with low and elevated PVR
has not yet been determined. To
address this hypothesis, high
pulmonary vascular resistance
(H-PVR) patients with HF were
compared with matched low pul-
monary vascular resistance (L-
PVR) patients. To further eluci-
date the link between cGMP
catabolism and pulmonary he-
modynamics, H-PVR subjects
were also studied after the ad-
ministration of the phospho-
diesterase (PDE)-5A inhibitor
sildenafil.
Methods
Patients with symptomatic HF
due to LV dysfunction (ejection
fraction 35%) with either
L-PVR or H-PVR (200 or
200 dyn·s·cm5) (1) were ex-
amined. Subjects with L-PVR
ere identified from a larger HF cohort to match clinical
haracteristics (age, sex, body size, disease severity, and right
trial pressure) of H-PVR patients. The protocol was
pproved by a local ethics committee. All patients were
ormoxemic (oxygen saturation 90%) on room air. After
igning informed consent, a pulmonary artery (PA) catheter
Braun Melsungen AG, Melsungen, Germany) was inserted
nder fluoroscopic guidance, and samples were acquired
rom the right atrium, PA, and pulmonary vein (PV).
amples of PV were obtained by aspiration from a wedged
A catheter after discarding the initial 10 ml. Only samples
ith an oxygen saturation 95% by blood gas analysis were
ccepted. Cardiac output was measured by thermodilution
nd systemic blood pressure with an oscillometric cuff. In
he H-PVR group, the examination was repeated 1 h after
n oral dose of sildenafil citrate (40 mg) (Pfizer, New York,
ew York).
Blood samples in ethylenediamine tetraacetic acid were
mmediately centrifuged (4°C) and processed. We measured
GMP by the use of radioimmunoassay (Immunotech a.s.,
raha, Czech Republic) with a sensitivity of 0.2 pmol·l1,
nd we measured B-type natriuretic peptide (BNP) by
MIA (Architect BNP, Abbott, Abbott Park, Illinois) with
ensitivity of 10 ng·l1 and between-run imprecision of
.7%. Plasma norepinephrine was measured by radioimmu-
oassay (CAT-combi, DRG Instruments GmbH, Mar-
urg/Lahn, Germany).
The PVR was calculated as mean transpulmonary pres-
ure gradient/cardiac output. Compliance was determined
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
cGMP  cyclic guanosine
monophosphate
HF  heart failure
H-PVR  high pulmonary
vascular resistance
L-PVR  low pulmonary
vascular resistance
LV  left ventricular
NP  natriuretic peptide
PA  pulmonary artery
PDE  phosphodiesterase
PGE1  prostaglandin E1
PH  pulmonary
hypertension
PV  pulmonary vein
PVR  pulmonary vascular
resistances stroke volume/pulse pressure (10). Transpulmonary BNP
v
Aptake and cGMP release were calculated as: (BNPPA 
NPPV)  cardiac output  (1  hematocrit) and as
cGMPPV  cGMPPA)  cardiac output  (1  hemat-
crit), as reported previously (11).
Parameters with normal distribution (Shapiro-Wilks test)
ere tested by the use of paired/unpaired t tests and
eported as mean  SD. For abnormally distributed data
reported as medians and interquartile range), Mann-
hitney U or Wilcoxon tests were used. Pearson r or
pearman R (for abnormally distributed) was calculated for
orrelations. Nominal variables were compared between
roups with the chi-square test. General linear model was
sed for multivariate adjustments. A p value of 0.05 was
onsidered significant.
esults
total of 46 subjects with HF due to coronary artery disease
CAD; n  25) or nonischemic cardiomyopathy (n  21)
ere examined; 22 (48%) were in the H-PVR group (PVR
200 dyn·s·cm5).
eterminants of increased PVR. We found that CAD
ended to be more frequent in H-PVR, but other charac-
eristics, comorbidities, medication, and procedures (coro-
ary artery bypass grafting, device, or valve surgery) were
imilarly distributed (Table 1). We also found that PVR, the
ystemic vascular resistance/PVR ratio, transpulmonary gra-
ient, and pulmonary pulse pressure (41  12 mm Hg vs.
aseline CharacteristicsTable 1 Baseline Characteristics
Low PVR
(n  24)
High PVR
(n  22) p Value
Age, yrs 51 14 54 10 0.5
Male sex, % 88 82 0.6
Body mass index, kg/m2 26 5.2 27 4.4 0.5
Etiology: CAD/DCM, n 10/14 15/7 0.07
NYHA functional class 2.9 0.7 2.9 0.6 0.8
MLHFQ score 44 21 43 27 0.9
Peak VO2, ml·kg
1·min1* 16.0 4 14.2 3 0.2
Furosemide daily dose, mg† 80 (50–101) 101 (80–160) 0.06
Hemoglobin, g·l1 135 16 133 20 0.7
Serum creatinine, mol·l1 113 41 113 41 0.9
Diabetes/COPD/
pulmonary embolism, %
25/4/0 45/4/5 0.2/0.9/0.3
Beta-blockers/ACE or
AR inhibitors, %
75/62/12 91/54/23 0.2/0.6/0.4
Spironolactone/furosemide, % 75/96 73/100 0.9/0.3
Digoxin inotropes, % 17/21 36/19 0.1/0.9
Echocardiography
LV ejection fraction, % 23 4.8 22 3.5 0.4
LV end-diastolic diameter, mm 70 9 70 6 0.9
RV dysfunction grade, (0–3) 1.9 1 2.2 0.7 0.2
Mitral regurgitation grade, (0–5) 3.3 0.9 3.3 0.9 0.9
Available in 12 and 12 subjects. Unpaired t test (mean  SD) or †Mann-Whitney U test (median
nd interquartile range), chi-square test for nominal variables.
ACE  angiotensin-converting enzyme; AR  angiotensin receptor; CAD  coronary artery
isease; COPD chronic obstructive pulmonary disease; DCM dilated cardiomyopathy; LV left
entricular; MLHFQMinnesota Living With Heart Failure Questionnaire; NYHA New York Heart
ssociation; PVR  pulmonary vascular resistance; RV  right ventricular; VO2  oxygen uptake.
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August 11, 2009:595–600 Pulmonary Hypertension in HF2  7 mm Hg; p  0.0001) were all increased in patients
ith H-PVR (Table 2). Pulmonary and systemic arterial
ompliance (Fig. 1A) were lower in patients with H-PVR.
n all, PVR correlated with cardiac output, systemic vascular
esistance, and PA mean and wedge pressure (R  0.47,
.34, 0.86, and 0.46, respectively).
Valid PA samples were obtained from 18 H-PVR and
9 L-PVR subjects (Table 3). The levels of BNP and
GMP correlated in the right atrium, PA, and PV of the
-PVR patients (R  0.5 to 0.6; all p  0.05), but not
f the H-PVR (R  0.3 to 0.5; all p  0.05). Transpul-
onary BNP uptake was similar (p 0.2), but cGMP release
aseline Hemodynamic Parameters in HF PatientsTable 2 Baseline Hemodynamic Parameters in HF Patients
Low PVR
(n  24)
High PVR
(n  22) p Value
Heart rate, min1 78 15 82 14 0.4
Right atrial pressure, mean,
mm Hg
6.4 5.7 8.7 3.7 0.1
PA pressure, mean, mm Hg 24 8.7 46 6.4 0.0001
PA wedge pressure, mean,
mm Hg*
15.5 (8.5–25) 26.5 (22–29) 0.0001
Transpulmonary pressure
gradient, mm Hg*
7.5 (6–9) 20 (15–24) 0.0001
PVR, dyn·s·cm5* 137 (110–171) 416 (296–607) —
Pulmonary arterial compliance,
ml·mm Hg1*
2.46 (2.0–3.3) 1.29 (0.8–1.5) 0.0001
SVR, dyn·s·cm-5 1,609 502 1,750 553 0.4
Systemic arterial compliance,
dyn·s·cm5*
1.41 (1.2–1.7) 1.10 (0.7–1.4) 0.03
SVR/PVR ratio* 11.7 (8.1–14.7) 3.8 (3.0–4.9) 0.0001
Systemic blood pressure,
mean, mm Hg
89 18 85 14 0.6
Cardiac index, l·min1·m2 2.14 0.4 1.83 0.4 0.01
npaired t test (mean  SD) or *Mann-Whitney U test (median and interquartile range).
PA  pulmonary artery; SVR  systemic vascular resistance; other abbreviations as in Table 1.
 
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Figure 1 Pulmonary and Systemic Arterial Compliances and the
(A) Pulmonary and systemic arterial compliance in HF patients with low or high PV
PVR and transpulmonary cGMP release in L-PVR (green) and H-PVR (red) patients.
cular resistance.27.8  31 nmol·min1 vs. 1.9  29 nmol·min1; p 
.005) was significantly greater in the L-PVR patients (Fig.
A), even after adjustment to PA wedge pressure (p 0.003),
iabetes, CAD, and digoxin and beta-blocker use (p 0.004).
n all, transpulmonary cGMP release correlated with PVR
Fig. 1B) but not with PA wedge pressure (R  0.1, p
0.5). Transpulmonary BNP uptake correlated with
GMP release in the L-PVR (R  0.62, p  0.004) but
ot in the H-PVR (R  0.1, p  0.7). Plasma norepi-
ephrine in age-, sex-, and etiology-matched L-PVR and
-PVR subgroups (n  12 and n  14) were similar (2.5
1.4 nmol·l1 vs. 2.4  0.9 nmol·l1; p  0.8).
ffects of sildenafil. Oral administration of 40 mg of
ildenafil to 16 H-PVR patients reduced PVR (42%) and
ranspulmonary gradient (39%) and increased cardiac
ndex (24%), stroke volume (33%), and PA compliance
87%) (Fig. 3A, Table 4). The reduction in PVR was
nversely related to baseline PVR (r  0.71, p  0.001)
nd unrelated to the change of PA wedge pressure (r 
.02, p  0.9). Patients below and above a median of
aseline PA wedge pressure had a similar PVR decrease
254 dyn·s·cm5 vs. 309 dyn·s·cm5, p  0.5). We
ound that PA compliance had an inverse, hyperbolic
elation to PVR (Fig. 3B).
According to a recent (5  27 days) clinically indicated
ulmonary vasodilation test with prostaglandin E1 (PGE1)
alprostadil, peak rate of 275  100 ng·kg1·min1),
atients were labeled as having reversible (final PVR 240
yn·s·cm5 and TPG 15 mm Hg), partially reversible
only 1 criterion met), or irreversible PH (both criteria not
et). The PGE1-irreversible (n  8) and completely or
artially PGE1-reversible patients (n  8) did not differ by
aseline PVR (p  0.13), transpulmonary cGMP release
p  0.71), or BNP uptake (p  0.71). Sildenafil-induced
R 	    




pulmonary cGMP release
nmol.min-1 

  	 
p = 0.01

ation of PVR to Transpulmonary cGMP Release
00 or 200 dyn·s·cm5), median  interquartile range. (B) Correlation between
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Pulmonary Hypertension in HF August 11, 2009:595–600VR response was similar in PGE1-irreversible or
reversible (partially or completely) patients (PVR:
290  98 dyn·s·cm5 vs. 245  182 dyn·s·cm5; p 
.54). Valid paired PA samples were obtained from 11
ubjects. Sildenafil had no effect on transpulmonary BNP
ptake, but it increased cGMP release (from 5.6  33
mol·min1 to 16.5  39 nmol·min1, p  0.047)
Table 3, Fig. 2B). Plasma norepinephrine did not
hange after sildenafil (from 2.7  0.6 nmol·l1 to 2.4 
.2 nmol·l1; p  0.4).
ocal Concentrations of BNP and cGMP at the BaselineTable 3 Local Concentrations of BNP and cGMP at the Baselin
RA PA
BNP, ng·l1*
L-PVR 244 (79–472) 207 (83–472)
H-PVR 480 (308–778) 489 (298–659)
p value L-PVR  H-PVR 0.06 0.04
cGMP, nmol·l1
L-PVR 12.2 8 12.7 11
H-PVR 14.6 7 22.2 11
p value L-PVR  H-PVR NS 0.01
iochemical data were available from 19 low-pulmonary vascular resistance (L-PVR) and 18 high-p
test or *Wilcoxon test (lines). Values are mean (SD) or *median (interquartile range).
BNP B-type natriuretic peptide; cGMP cyclic guanosine monophosphate; NS p value0.1;
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Figure 2 Transpulmonary BNP Uptake and cGMP Release
(A) Transpulmonary BNP uptake (median  interquartile range) and cGMP
release (mean  SD) in HF patients with low or high PVR (200 or 200
dyn·s·cm-5). (B) Transpulmonary BNP uptake and cGMP release in the H-PVR
group before and after administration of 40 mg of sildenafil. BNP  B-type
natriuretic peptide; other abbreviations as in Figure 1.riscussion
ur first aim was to identify specific features of H-PVR
atients by comparing them with their L-PVR counterparts
atched for many clinical characteristics. Although pulmo-
ary BNP uptake was similar, cGMP release was dimin-
shed in H-PVR group. Although a previous analysis (11)
ound that pulmonary cGMP production is uncoupled from
trial natriuretic peptide uptake in advanced HF, our study
s the first to explicitly link reduced pulmonary cGMP
elease to high PVR in patients with HF.
Cyclic GMP serves as a mediator of vasodilation in
ulmonary vessels and is synthesized by soluble guanylate
yclase (in response to nitric oxide) or by membrane-bound
uanylate cyclase of the NP receptor. Because some cGMP
scapes the cells by multidrug-resistance protein transport-
rs (12), its plasma level provides an estimate of intracellular
esponse to cGMP-dependent vasodilators.
Tissue effects of NP become attenuated with the progres-
ion of HF. This “NP resistance” is due to enhanced NP
learance, decreased NP receptor downstream signaling, or
nhanced cGMP degradation by intracellular PDEs (8).
he last mechanism is probably the most relevant here
ecause cGMP-selective PDE5A is abundant in pulmonary
issue (13) and its activity further increases with HF
rogression (9). Marked responsiveness of PVR to PDE5A
nhibition observed in this study and others (14,15) support
his notion. In our study, pulmonary cGMP release corre-
ated with BNP uptake in the L-PVR but not in the
-PVR group, indicating profound pulmonary NP resis-
ance in the latter. This finding also explains why nesiritide
herapy had no effect on the pulmonary hemodynamics in
F patients with pre-capillary PH (16). Interestingly,
-PVR patients had markedly reduced PA compliance,
ndicating diminished elasticity of PA tree and also lower
ystemic arterial compliance, suggesting that arterial stiff-
ning affects both vascular territories.
Our second objective was to investigate the effects of
ildenafil. Sildenafil reduced PVR even in patients not
xhibiting PH reversibility with PGE1 (Fig. 3A). The
p Value
PV RA  PA PV  RA PV  PA
186 (91–536) NS NS 0.04
446 (228–655) NS 0.05 0.02
0.06 — — —
24.2 21 NS 0.005 0.0005
20.7 10 0.02 NS NS
NS — — —
ry vascular resistance (H-PVR) subjects. Unpaired t test or *Mann-Whitney U test (columns), paired
ulmonary artery; PV pulmonary vein; RA right atrium; other abbreviations as in Tables 1 and 2.e
ulmonaesults are in agreement with the growing notion that even
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August 11, 2009:595–600 Pulmonary Hypertension in HFfixed” PVR elevation in many HF patients is eventually
eversible after prolonged LV unloading (17) or perhaps
ith pulmonary-selective vasodilators. The PVR reduction
as also independent of baseline PA wedge pressure or its
hange. Although long-term elevation of left atrial pressure
an increase PVR, particularly in mitral stenosis (18), our
ata do not indicate that actual LA pressure has a direct role
n acute pulmonary vasomotor response to sildenafil.
Figure 3 Hemodynamic Responses to Sildenafil
(A) Individual responses to 40 mg of sildenafil in H-PVR patients. Red lines  PGE1
of pulmonary arterial compliance to PVR before (red) and after (blue) sildenafil. PGE1
ffect of 40-mg Sildenafil Dose in H-PVR PatientsTable 4 Effect of 40-mg Sildenafil Dose in H-PVR Patients
Baseline Sildenafil p Value
Heart rate, min1 81 15 74 12 0.003
PA pressure, mean, mm Hg 48 6 37 8 0.001
PA wedge pressure, mean, mm Hg* 26 (22–29) 25 (19–27) 0.20
PVR, dyn·s·cm5 341 (356–641) 243 (185–339) 0.001
Transpulmonary pressure gradient,
mm Hg*
23 (19–26) 12 (10–18) 0.001
Pulmonary arterial compliance,
ml·mm Hg1*
1.03 (0.8–1.3) 1.9 (1.5–2.1) 0.001
SVR, dyn·s·cm5 1823 593 1352 455 0.001
SVR/PVR ratio* 3.7 (2.9–4.0) 5.2 (3.4–6.3) 0.002
Systemic blood pressure, mean,
mm Hg
86 12 79 10 0.003
Cardiac index, l·min1·m2 1.8 0.4 2.2 0.6 0.001
Stroke volume, ml 46 14 61 15 0.001
BNP, ng·l1*
RA 525 (365–768) 403 (317–732) 0.6
PA 543 (298–659) 458 (375–759) 0.6
PV 514 (228–581) 378 (263–640) 0.7
cGMP, nmol·l1
RA 14.7 7.7 14.4 6.7 0.9
PA 24.5 13 18.8 6.9 0.03
PV 20.6 11 24.6 14 0.4
aired t test or *Wilcoxon test. Mean  SD or *median (interquartile range) are reported. PairedT
iochemical data were available from 11 subjects.
Abbreviations as in Tables 1 to 3.Sildenafil markedly affected PA compliance, a parameter
hat characterizes elasticity of pulmonary arterial tree and
ulsatile loading of the right ventricle. The nonlinear,
yperbolic relationship between PVR and PA compliance
Fig. 3B) suggests that relatively small change of PVR after
ildenafil may be associated with large increase in PA
ompliance, particularly among patients within lower PVR
ange. In idiopathic PH, PA compliance is a strong predic-
or of mortality (19), so its improvement in HF patients
ight impact prognosis as well.
Sildenafil increased cardiac index (24%), mainly by
ncreasing stroke volume. Greater contractility, reduced
fterload, or diminished interventricular interaction (20)
ould be involved, but the latter 2 mechanisms are more
lausible than the former. Previously, sildenafil did not
hange LV dP/dtmax in HF patients with PH (15), and it
ctually blunted dobutamine-stimulated contractile re-
ponse in healthy adults (21). Although sympathetic
ctivation and increase of plasma norepinephrine after
ildenafil was described in healthy volunteers (22), this
eport and another (23) show no such evidence in
atients with HF.
Several short-term studies in HF patients (2,14,24) re-
ently showed favorable effects of sildenafil on pulmonary
emodynamics, exercise tolerance and quality of life without
erious side effects. Therefore, PDE5 inhibitors seem to be
romising drugs for selected HF patients, particularly in
eritransplant settings, but long-term safety remains un-
nown, and they require testing before their use in the
eneral HF population.
tudy limitations. First, pulmonary cGMP production
as estimated from spillover into the bloodstream, and this
pproach likely underestimates intracellular changes.
rsible PH; green lines  PGE1-reversible PH (partially or completely). (B) Relation
staglandin E1; PH  pulmonary hypertension; other abbreviations as in Figure 1.-irreve
 proranspulmonary cGMP release was even negative in some
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Pulmonary Hypertension in HF August 11, 2009:595–600ubjects, which may reflect the assay variation but also
ntravascular degradation or cellular reuptake of cGMP
12). Second, the sample size is relatively small, and type 2
rror limits more detailed analyses. Third, groups were not
ompletely balanced in some covariates, but they differed in
GMP release even after multivariate adjustments. Fourth,
ome have argued that the transpulmonary gradient is a
ore appropriate measure of forces opposing blood flow
han PVR (25). When data were reanalyzed with the use of
12-mm Hg transpulmonary gradient cut-off instead of a
VR cut-off, the main findings of the study remained
nchanged.
onclusions
atients with HF and increased PVR are characterized by
ncreased stiffness of systemic and pulmonary arteries, pre-
erved transpulmonary BNP uptake, but diminished cGMP
elease that is reversible by acute PDE5A inhibition. This
tudy provides human in vivo evidence that the use of
ildenafil restores sensitivity of pulmonary vasculature to
ndogenous cGMP-dependent vasodilators.
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